Loading...
Header Logo
Keywords
Last Name
Institution

Lisa Ann Cavacini PhD

TitleProfessor
InstitutionUniversity of Massachusetts Medical School
DepartmentMedicine
AddressMassBiologics
460 Walk Hill Street
Boston MA 02126
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentMedicine
    DivisionMassachusetts Biological Laboratory

    InstitutionUMMS - Graduate School of Biomedical Sciences
    DepartmentImmunology and Microbiology Program


    Collapse Biography 
    Collapse education and training
    University of Scranton, Scranton, PA, United StatesBSBiology
    Drexel University, Philadelphia, PA, United StatesPHDMicrobiology/Immunology

    Collapse Overview 
    Collapse overview

    The major focus of my laboratory research is in the area of immunoregulation of infectious disease, cancer and autoimmune disease. Human monoclonal antibodies are characterized to study the humoral immune response in these disorders. . In addition, the laboratory is interested in developing active and passive forms of immunotherapy for the treatment of these disease areas. Not only do we generate new human monoclonal antibodies for our studies, but also for a large number of laboratories throughout the world for research on infectious diseases, cancer and autoimmune disease. We collaborate with Drs. Greiner, Brehm and Luban here at UMMS and Dr. Leonard Schultz at Jackson Laboratories on humanized mouse models for the generation of human monoclonal antibodies and as models for passive immunotherapy for bacterial or viral infections. The laboratory has also been involved in pharmacokinetic and pharmacodynamic studies of IgG and IgA human monoclonal antibodies, in several bacterial and viral infections. To further develop Dr. Cavacini’s background in mucosal immunology, included in this work is structural modeling of antibody/antigen interactions to improve the design of immunotherapeutic antibodies and development of a platform for production of dimeric and secretory IgA. These leading activities in IgA immunotherapy are currently being translated into clinical development of mucosal IgA molecules for prevention or treatment of two diverse bacterial infections. In addition to Dr. Cavacini’s current work on immunoprophylaxis for mucosal bacterial infections (e.g. Enterotoxigenic Escherichia coli,, Bordetella pertussis, Klebsiella pneumonia), she is also inventor of two human monoclonal antibodies against Staphylococcus aureus and Pseudomonas aeruginosa. Dr. Cavacini also contributes to programs for Lyme Disease and other emerging pathogens. Most recently, this has been to generate reagents and establish assays for screening novel drug candidates for immunoprophylaxis or treatment of COVID-19. Our initial screen of MassBiologics’ existing panel of SARS-CoVspecific antibodies resulted in Mabs with ELISA binding activity to the receptor binding domain of the SARS-CoV-2 Spike protein.  We have moved on to nanobody discovery for broadly neutralizing antibodies against all variants of concern and interest.  The expertise at MassBiologics, particularly in the areas of Discovery and Process Development, has allowed rapid production of SARS CoV-2 proteins (including several spike proteins and N protein) and human antibodies and nanobodies , contributing to the evaluation and development of therapeutics and diagnostics.



    Collapse Rotation Projects

    Rotation projects include development of nanobodies for prevention and treatment of mucosal disease (viral and bacteria).




    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schiller ZA, Rudolph MJ, Toomey JR, Ejemel M, LaRochelle A, Davis SA, Lambert HS, Kern A, Tardo AC, Souders CA, Peterson E, Cannon RD, Ganesa C, Fazio F, Mantis NJ, Cavacini LA, Sullivan-Bolyai J, Hu LT, Embers ME, Klempner MS, Wang Y. Blocking Borrelia burgdorferi transmission from infected ticks to non-human primates with a human monoclonal antibody. J Clin Invest. 2021 Apr 29. PMID: 33914704.
      View in: PubMed
    2. Amcheslavsky A, Wallace AL, Ejemel M, Li Q, McMahon CT, Stoppato M, Giuntini S, Schiller ZA, Pondish JR, Toomey JR, Schneider RM, Meisinger J, Heukers R, Kruse AC, Barry EM, Pierce BG, Klempner MS, Cavacini LA, Wang Y. Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design. Sci Rep. 2021 Feb 02; 11(1):2751. PMID: 33531570.
      View in: PubMed
    3. Teh AY, Cavacini L, Hu Y, Kumru OS, Xiong J, Bolick DT, Joshi SB, Grünwald-Gruber C, Altmann F, Klempner M, Guerrant RL, Volkin DB, Wang Y, Ma JK. Investigation of a monoclonal antibody against enterotoxigenic Escherichia coli, expressed as secretory IgA1 and IgA2 in plants. Gut Microbes. 2021 Jan-Dec; 13(1):1-14. PMID: 33439092.
      View in: PubMed
    4. Ejemel M, Gawron MA, Schneider MI, Wallace A, Schiller ZA, Schneider R, Martin JC, Klempner MS, Wang Y, Cavacini LA. Highly Specific Mouse Anti-Joining Chain of Human Immunoglobulin A. Monoclon Antib Immunodiagn Immunother. 2020 Oct 29. PMID: 33121367.
      View in: PubMed
    5. Wallace AL, Schneider MI, Toomey JR, Schneider RM, Klempner MS, Wang Y, Cavacini LA. IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability. Vaccine. 2020 Oct 08. PMID: 33041102.
      View in: PubMed
    6. Laible G, Cole S, Brophy B, Maclean P, How Chen L, Pollock DP, Cavacini L, Fournier N, De Romeuf C, Masiello NC, Gavin WG, Wells DN, Meade HM. Transgenic goats producing an improved version of cetuximab in milk. FASEB Bioadv. 2020 Nov; 2(11):638-652. PMID: 33205005.
      View in: PubMed
    7. Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, Amcheslavsky A, Kurt Yilmaz N, Buttigieg KR, Elmore MJ, Godwin K, Coombes N, Toomey JR, Schneider R, Ramchetty AS, Close BJ, Chen DY, Conway HL, Saeed M, Ganesa C, Carroll MW, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun. 2020 Aug 21; 11(1):4198. PMID: 32826914.
      View in: PubMed
    8. Ejemel M, Li Q, Hou S, Schiller ZA, Wallace AL, Amcheslavsky A, Yilmaz NK, Toomey JR, Schneider R, Close BJ, Chen DY, Conway HL, Mohsan S, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. bioRxiv. 2020 May 15. PMID: 32511396.
      View in: PubMed
    9. Stoppato M, Gaspar C, Regeimbal J, Nunez RG, Giuntini S, Schiller ZA, Gawron MA, Pondish JR, Martin JC, Schneider MI, Klempner MS, Cavacini LA, Wang Y. Oral administration of an anti-CfaE secretory IgA antibody protects against Enterotoxigenic Escherichia coli diarrheal disease in a nonhuman primate model. Vaccine. 2020 Jan 30. PMID: 32008877.
      View in: PubMed
    10. Hu Y, Kumru OS, Xiong J, Antunez LR, Hickey J, Wang Y, Cavacini L, Klempner M, Joshi SB, Volkin DB. Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration. J Pharm Sci. 2019 Jul 29. PMID: 31369743.
      View in: PubMed
    11. Gawron MA, Duval M, Carbone C, Jaiswal S, Wallace A, Martin JC, Dauphin A, Brehm MA, Greiner DL, Shultz LD, Luban J, Cavacini LA. Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1. J Immunol. 2018 Dec 28. PMID: 30593536.
      View in: PubMed
    12. Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD, Barry EM, Cavacini LA, Klempner MS, Wang Y. Correction for Giuntini et al., "Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection". Infect Immun. 2018 Dec; 86(12). PMID: 30459206.
      View in: PubMed
    13. Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD, Barry EM, Cavacini LA, Klempner MS, Wang Y. Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis Against Enterotoxigenic Escherichia coli Infection. Infect Immun. 2018 Jun 04. PMID: 29866909.
      View in: PubMed
    14. Yu X, Duval M, Gawron M, Posner MR, Cavacini LA. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition. J Immunol Res. 2016; 2016:9425172. PMID: 27419146.
      View in: PubMed
    15. Lo AS, Mao X, Mukherjee EM, Ellebrecht CT, Yu X, Posner MR, Payne AS, Cavacini LA. Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris. PLoS One. 2016; 11(6):e0156800. PMID: 27304671.
      View in: PubMed
    16. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016 Mar 4; 351(6277):1078-83. PMID: 26912366.
      View in: PubMed
    17. Cho MJ, Lo AS, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS. Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nat Commun. 2014 Jun 19; 5:4167. PMID: 24942562.
      View in: PubMed
    18. Farr C, Nomellini JF, Ailon E, Shanina I, Sangsari S, Cavacini LA, Smit J, Horwitz MS. Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors. PLoS One. 2013; 8(6):e65965. PMID: 23840383.
      View in: PubMed
    19. Yu X, Pollock D, Duval M, Lewis C, Joseph K, Meade H, Cavacini L. Neutralization of HIV by milk expressed antibody. J Acquir Immune Defic Syndr. 2013 Jan 1; 62(1):10-6. PMID: 23269241.
      View in: PubMed
    20. Yu X, Duval M, Lewis C, Gawron MA, Wang R, Posner MR, Cavacini LA. Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. J Immunol. 2013 Jan 1; 190(1):205-10. PMID: 23183895.
      View in: PubMed
    21. Duval M, Lewis CJ, Nomellini JF, Horwitz MS, Smit J, Cavacini LA. Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus. Antimicrob Agents Chemother. 2011 Dec; 55(12):5547-52. PMID: 21896905.
      View in: PubMed
    22. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A. 2011 Jul 5; 108(27):11181-6. PMID: 21690411.
      View in: PubMed
    23. Nomellini JF, Li C, Lavallee D, Shanina I, Cavacini LA, Horwitz MS, Smit J. Development of an HIV-1 specific microbicide using Caulobacter crescentus S-layer mediated display of CD4 and MIP1alpha. PLoS One. 2010; 5(4):e10366. PMID: 20442778.
      View in: PubMed
    24. Schroeder HW, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010 Feb; 125(2 Suppl 2):S41-52. PMID: 20176268.
      View in: PubMed
    25. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009 Nov 20; 326(5956):1123-7. PMID: 19965434.
      View in: PubMed
    26. Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology. 2008 Nov 25; 381(2):251-60. PMID: 18822440.
      View in: PubMed
    27. Duval M, Posner MR, Cavacini LA. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J Virol. 2008 May; 82(9):4671-4. PMID: 18272577.
      View in: PubMed
    28. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol. 2008 Jan 25; 375(4):969-78. PMID: 18068724.
      View in: PubMed
    29. Miranda LR, Duval M, Doherty H, Seaman MS, Posner MR, Cavacini LA. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J Immunol. 2007 Jun 1; 178(11):7132-8. PMID: 17513762.
      View in: PubMed
    30. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology. 2007 Aug 1; 364(2):441-53. PMID: 17418361.
      View in: PubMed
    31. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006 Oct 26; 355(17):1772-9. PMID: 17065638.
      View in: PubMed
    32. Ferrantelli F, Buckley KA, Rasmussen RA, Chalmers A, Wang T, Li PL, Williams AL, Hofmann-Lehmann R, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology. 2007 Feb 5; 358(1):69-78. PMID: 16996554.
      View in: PubMed
    33. Kelly-Quintos C, Cavacini LA, Posner MR, Goldmann D, Pier GB. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun. 2006 May; 74(5):2742-50. PMID: 16622211.
      View in: PubMed
    34. Yeh SW, Cavacini LA, Bhol KC, Lin MS, Kumar M, Duval M, Posner MR, Ahmed AR. Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol. 2006 Jul; 120(1):68-75. PMID: 16635589.
      View in: PubMed
    35. Liu F, Kumar M, Ma Q, Duval M, Kuhrt D, Junghans R, Posner M, Cavacini L. Human single-chain antibodies inhibit replication of human immunodeficiency virus type 1 (HIV-1). AIDS Res Hum Retroviruses. 2005 Oct; 21(10):876-81. PMID: 16225415.
      View in: PubMed
    36. Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, Lawrence CM. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol. 2005 Oct; 79(20):13060-9. PMID: 16189008.
      View in: PubMed
    37. Cavacini LA, Duval M, Patil A, Wood C, Mayer KH, Ruprecht RM, Posner MR. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy. J Med Virol. 2005 Jun; 76(2):146-52. PMID: 15834877.
      View in: PubMed
    38. Cao W, Cavacini LA, Tillman KC, Posner MR. CD40 function in squamous cell cancer of the head and neck. Oral Oncol. 2005 May; 41(5):462-9. PMID: 15878750.
      View in: PubMed
    39. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6. PMID: 15598588.
      View in: PubMed
    40. Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 2004 Nov 1; 173(9):5671-8. PMID: 15494518.
      View in: PubMed
    41. Cavacini L, Posner M. Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. AIDS Res Hum Retroviruses. 2004 Apr; 20(4):435-41. PMID: 15157362.
      View in: PubMed
    42. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, Stiegler G, Cavacini LA, Bai Y, Cotropia J, Ugen KE, Ruprecht RM. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. J Infect Dis. 2004 Jan 1; 189(1):71-4. PMID: 14702155.
      View in: PubMed
    43. Cavacini LA, Kuhrt D, Duval M, Mayer K, Posner MR. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res Hum Retroviruses. 2003 Sep; 19(9):785-92. PMID: 14585209.
      View in: PubMed
    44. Liu F, Bergami PL, Duval M, Kuhrt D, Posner M, Cavacini L. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res Hum Retroviruses. 2003 Jul; 19(7):597-607. PMID: 12908937.
      View in: PubMed
    45. Cavacini L, Duval M, Song L, Sangster R, Xiang SH, Sodroski J, Posner M. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS. 2003 Mar 28; 17(5):685-9. PMID: 12646791.
      View in: PubMed
    46. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS. 2003 Feb 14; 17(3):301-9. PMID: 12556683.
      View in: PubMed
    47. Kitabwalla M, Ferrantelli F, Wang T, Chalmers A, Katinger H, Stiegler G, Cavacini LA, Chou TC, Ruprecht RM. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses. 2003 Feb; 19(2):125-31. PMID: 12639248.
      View in: PubMed
    48. Cavacini LA, Duval M, Robinson J, Posner MR. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS. 2002 Dec 6; 16(18):2409-17. PMID: 12461414.
      View in: PubMed
    49. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Jiang S, Li PL, Baba TW, Montefiori DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Ruprecht RM. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol. 2002 Jun; 31(3):109-19. PMID: 12190851.
      View in: PubMed
    50. Cavacini LA, Duval M, Eder JP, Posner MR. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin Cancer Res. 2002 Feb; 8(2):368-73. PMID: 11839651.
      View in: PubMed
    51. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou TC, Ruprecht RM. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol. 2001 Aug; 30(4):190-6. PMID: 11555137.
      View in: PubMed
    52. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, Ferrantelli F, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Chou TC, Andersen J, Ruprecht RM. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol. 2001 Aug; 75(16):7470-80. PMID: 11462019.
      View in: PubMed
    53. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, Vlasak J, Xu W, Baba TW, Chenine AL, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Montefiori DC, McClure HM. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol. 2001 Aug; 8(4):350-8. PMID: 11642027.
      View in: PubMed
    54. Xu W, Smith-Franklin BA, Li PL, Wood C, He J, Du Q, Bhat GJ, Kankasa C, Katinger H, Cavacini LA, Posner MR, Burton DR, Chou TC, Ruprecht RM. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol. 2001 Mar-Apr; 4(2):55-61. PMID: 11437315.
      View in: PubMed
    55. Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol. 2000 Dec; 74(23):11008-16. PMID: 11069996.
      View in: PubMed
    56. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000 Feb; 6(2):200-6. PMID: 10655110.
      View in: PubMed
    57. Cavacini LA, Wisnewski A, Peterson JE, Montefiori D, Emes C, Duval M, Kingsbury G, Wang A, Scadden D, Posner MR. A human anti-HIV autoantibody enhances EBV transformation and HIV infection. Clin Immunol. 1999 Dec; 93(3):263-73. PMID: 10600338.
      View in: PubMed
    58. Cavacini LA, Peterson JE, Nappi E, Duval M, Goldstein R, Mayer K, Posner MR. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals. J Virol. 1999 Nov; 73(11):9638-41. PMID: 10516076.
      View in: PubMed
    59. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res. 1999 Aug; 5(8):2261-70. PMID: 10473114.
      View in: PubMed
    60. Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, Posner MR. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses. 1998 Sep 20; 14(14):1271-80. PMID: 9764911.
      View in: PubMed
    61. Deng B, Banu N, Malloy B, Hass P, Wang JF, Cavacini L, Eaton D, Avraham H. An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. Blood. 1998 Sep 15; 92(6):1981-8. PMID: 9731056.
      View in: PubMed
    62. Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, Hammer S, Koziel C, Trapnell C, Posner MR. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses. 1998 May 1; 14(7):545-50. PMID: 9591708.
      View in: PubMed
    63. Li A, Katinger H, Posner MR, Cavacini L, Zolla-Pazner S, Gorny MK, Sodroski J, Chou TC, Baba TW, Ruprecht RM. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol. 1998 Apr; 72(4):3235-40. PMID: 9525650.
      View in: PubMed
    64. Franken M, Estabrooks A, Cavacini L, Sherburne B, Wang F, Scadden DT. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat Med. 1996 Dec; 2(12):1379-82. PMID: 8946840.
      View in: PubMed
    65. Wolfe EJ, Cavacini LA, Samore MH, Posner MR, Kozial C, Spino C, Trapnell CB, Ketter N, Hammer S, Gambertoglio JG. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin Pharmacol Ther. 1996 Jun; 59(6):662-7. PMID: 8681491.
      View in: PubMed
    66. Wisnewski A, Cavacini L, Posner M. Human antibody variable region gene usage in HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1; 11(1):31-8. PMID: 8528730.
      View in: PubMed
    67. Cavacini LA, Emes CL, Power J, Desharnais FD, Duval M, Montefiori D, Posner MR. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. J Immunol. 1995 Oct 1; 155(7):3638-44. PMID: 7561063.
      View in: PubMed
    68. Khouri YF, McIntosh K, Cavacini L, Posner M, Pagano M, Tuomala R, Marasco WA. Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest. 1995 Feb; 95(2):732-7. PMID: 7860754.
      View in: PubMed
    69. Cavacini LA, Power J, Emes CL, Mace K, Treacy G, Posner MR. Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. J Immunother Emphasis Tumor Immunol. 1994 May; 15(4):251-6. PMID: 8061897.
      View in: PubMed
    70. Cavacini LA, Emes CL, Power J, Duval M, Posner MR. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. J Immunol. 1994 Mar 1; 152(5):2538-45. PMID: 7510748.
      View in: PubMed
    71. Thali M, Charles M, Furman C, Cavacini L, Posner M, Robinson J, Sodroski J. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol. 1994 Feb; 68(2):674-80. PMID: 7507184.
      View in: PubMed
    72. Potts BJ, Field KG, Wu Y, Posner M, Cavacini L, White-Scharf M. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology. 1993 Nov; 197(1):415-9. PMID: 8212576.
      View in: PubMed
    73. Cavacini LA, Emes CL, Power J, Underdahl J, Goldstein R, Mayer K, Posner MR. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. J Acquir Immune Defic Syndr. 1993 Oct; 6(10):1093-102. PMID: 7692037.
      View in: PubMed
    74. Montefiori DC, Graham BS, Zhou J, Zhou J, Bucco RA, Schwartz DH, Cavacini LA, Posner MR. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. J Clin Invest. 1993 Aug; 92(2):840-7. PMID: 8349820.
      View in: PubMed
    75. Cavacini LA, Emes CL, Power J, Buchbinder A, Zolla-Pazner S, Posner MR. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr. 1993 Apr; 6(4):353-8. PMID: 8455141.
      View in: PubMed
    76. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr. 1993 Jan; 6(1):7-14. PMID: 8417177.
      View in: PubMed
    77. Cavacini LA, Giles-Komar J, Kennel M, Quinn A. Effect of immunosuppressive therapy on cytolytic activity of immunodeficient mice: implications for xenogeneic transplantation. Cell Immunol. 1992 Oct 15; 144(2):296-310. PMID: 1394445.
      View in: PubMed
    78. Cavacini LA, Kennel M, Lally EV, Posner MR, Quinn A. Human immunoglobulin production in immunodeficient mice: enhancement by immunosuppression of host and in vitro activation of human mononuclear cells. Clin Exp Immunol. 1992 Oct; 90(1):135-40. PMID: 1395094.
      View in: PubMed
    79. Marasco WA, Bagley J, Zani C, Posner M, Cavacini L, Haseltine WA, Sodroski J. Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest. 1992 Oct; 90(4):1467-78. PMID: 1401079.
      View in: PubMed
    80. Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retroviruses. 1992 May; 8(5):553-8. PMID: 1381201.
      View in: PubMed
    81. Cavacini LA, Parke LA, Weidanz WP. Resolution of acute malarial infections by T cell-dependent non-antibody-mediated mechanisms of immunity. Infect Immun. 1990 Sep; 58(9):2946-50. PMID: 2387628.
      View in: PubMed
    82. Weidanz WP, Melancon-Kaplan J, Cavacini LA. Cell-mediated immunity to the asexual blood stages of malarial parasites: animal models. Immunol Lett. 1990 Aug; 25(1-3):87-95. PMID: 2126529.
      View in: PubMed
    83. Cavacini LA, Guidotti M, Parke LA, Melancon-Kaplan J, Weidanz WP. Reassessment of the role of splenic leukocyte oxidative activity and macrophage activation in expression of immunity to malaria. Infect Immun. 1989 Dec; 57(12):3677-82. PMID: 2553611; PMCID: PMC259889.
      View in: PubMed, PubMed Central
    84. Burns JM, Parke LA, Daly TM, Cavacini LA, Weidanz WP, Long CA. A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. J Immunol. 1989 Apr 15; 142(8):2835-40. PMID: 2467942.
      View in: PubMed
    85. Goldring JP, Brake DA, Cavacini LA, Long CA, Weidanz WP. Cloned T cells provide help for malaria-specific polyclonal antibody responses. Eur J Immunol. 1989 Mar; 19(3):559-61. PMID: 2468507.
      View in: PubMed
    86. Weidanz WP, Brake DA, Cavacini LA, Long CA. The protective role of T cells in immunity to malaria. Adv Exp Med Biol. 1988; 239:99-111. PMID: 3059780.
      View in: PubMed
    87. Cavacini LA, Long CA, Weidanz WP. T-cell immunity in murine malaria: adoptive transfer of resistance to Plasmodium chabaudi adami in nude mice with splenic T cells. Infect Immun. 1986 Jun; 52(3):637-43. PMID: 3086229.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Cavacini's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (319) concept(s)
    _
    Co-Authors Expand Description
    See all (11) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department